Drugs & Therapy Perspectives

, Volume 18, Issue 5, pp 6–9 | Cite as

Vasodilators and inotropes provide symptomatic relief for decompensated heart failure

Disease Management


Acute Pancreatitis Dobutamine Levosimendan Milrinone Decompensated Heart Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bennett SJ, Cordes DK, Westmoreland G, et al. Self-care strategies for symptom management in patients with chronic heart failure. Nurs Res 2000; 49(3): 139–45PubMedCrossRefGoogle Scholar
  2. 2.
    Mills RM, Hobbs RE. Drug treatment of patients with decompensated heart failure. Am J Cardiovasc Drugs 2001; 1(2): 119–25PubMedCrossRefGoogle Scholar
  3. 3.
    Bennett SJ, Hustler GA, Baker SL, et al. Characterization of the precipitants of hospitalization for heart failure decompensation. Am J Crit Care 1998; 7: 168–74PubMedGoogle Scholar
  4. 4.
    Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995; 333: 1190–5PubMedCrossRefGoogle Scholar
  5. 5.
    Ashton CM, Kuykendall DH, Johnson ML, et al. The association between the quality of in-patient care and early readmission. Ann Intern Med 1995; 122: 415–21PubMedGoogle Scholar
  6. 6.
    Harrison DG, Bates JN. The nitrovasodilators: new ideas about old drugs. Circulation 1993; 87: 1461–7PubMedCrossRefGoogle Scholar
  7. 7.
    Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999 Jul; 34(1): 155–62PubMedCrossRefGoogle Scholar
  8. 8.
    Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000 Jul 27; 343: 246–53PubMedCrossRefGoogle Scholar
  9. 9.
    Young JB. Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) study results [oral presentation]. 73rd Scientific Sessions of the American Heart Association; 2000 Nov 12–15: New OrleansGoogle Scholar
  10. 10.
    Lowes BD, Simon MA, Tsvetkova TO, et al. Inotropes in the beta-blocker era. Clin Cardiol 2000; 23 Suppl. III: 11–6Google Scholar
  11. 11.
    Loh E. Maximizing management of patients with decompensated heart failure. Clin Cardiol 2000; 23 Suppl. III: 1–5Google Scholar
  12. 12.
    Figgitt DP, Gillies PS, Goa KL. Levosimendan. Drugs 2001; 61(5): 613–27PubMedCrossRefGoogle Scholar
  13. 13.
    Follath F, Cleland JGF, Just H, et al. Efficacy and safety of intravenous levosimendan in severe low-output heart failure [abstract no. 3406]. Circulation 1999; 100(18) Suppl. I: I–646Google Scholar
  14. 14.
    Simdax — Orion Pharma. Dosing [online]. Available from: URL: [Accessed Feb 2001]
  15. 15.
    Nieminen MS. Levosimendan: a viewpoint. Drugs 2001; 61(5): 628–9CrossRefGoogle Scholar
  16. 16.
    Leier CV, Binkley PF. Parenteral inotropic support for advanced congestive heart failure. Prog Cardiovasc Dis 1998; 41: 207–24PubMedCrossRefGoogle Scholar
  17. 17.
    Diller PM, Smucker DR, David B. Comanagement of patients with congestive heart failure by family physicians and cardiologists: frequency, timing, and patients characteristics. J Fam Pract 1999; 48: 177–9Google Scholar
  18. 18.
    Evangelista LS, Doering LV, Dracup K. Usefulness of a history of tobacco and alcohol use in predicting multiple heart failure readmissions among veterans. Am J Cardiol 2000; 86: 1339–42PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Personalised recommendations